In a filing, Mind Medicine Inc revealed its Chief Executive Officer Barrow Robert unloaded Company’s shares for reported $0.14 million on Mar 25 ’25. In the deal valued at $6.74 per share,21,208 shares were sold. As a result of this transaction, Barrow Robert now holds 856,556 shares worth roughly $6.0 million.
Then, Karlin Daniel sold 6,836 shares, generating $46,075 in total proceeds. Upon selling the shares at $6.74, the Chief Medical Officer now owns 446,177 shares.
Before that, Sullivan Mark sold 6,576 shares. Mind Medicine Inc shares valued at $44,322 were divested by the Chief Legal Officer at a price of $6.74 per share. As a result of the transaction, Sullivan Mark now holds 316,621 shares, worth roughly $2.22 million.
Evercore ISI initiated its Mind Medicine Inc [MNMD] rating to an Outperform in a research note published on January 28, 2025; the price target was $23. A number of analysts have revised their coverage, including Chardan Capital Markets’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. ROTH MKM started covering the stock on July 24, 2024. It rated MNMD as “a Buy”.
Price Performance Review of MNMD
On Monday, Mind Medicine Inc [NASDAQ:MNMD] saw its stock jump 6.21% to $7.01. Over the last five days, the stock has gained 8.68%. Mind Medicine Inc shares have risen nearly 0.72% since the year began. Nevertheless, the stocks have fallen -22.71% over the past one year.
How much short interest is there in Mind Medicine Inc?
A steep rise in short interest was recorded in Mind Medicine Inc stocks on 2025-04-30, dropping by -0.6 million shares to a total of 10.74 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-31 was 11.34 million shares. There was a decline of -5.55%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on May 29, 2024 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $27 price target.
